Immune therapies for malignant mesothelioma.
Malignant mesothelioma (MM) is a rare disease which can develop in pleura, pericardium or peritoneum and in which the therapies available have limited efficacy and are associated with various side effects. Therefore, there is a need for more targeted and more effective therapies which are able to halt the disease progression. Among them immune therapies actively or passively directed against various structures of the MM cells seem to be particularly promising given their inhibitory potential demonstrated in both experimental and early clinical studies. Mesothelin in particular seem to be not only a biomarker of disease activity but also a therapeutic target. This review discusses the immune therapies currently investigated for MM.
Palliative Care-Interdisciplinary Department, Faculty of Medicine, University of Medicine and Pharmacy "Grigore T Popa", 16 Universitaţii Str, 700115, Iaşi, Romania.
Sabina Antonela
SA
Antoniu
Gabriel
G
Dimofte
Didona
D
Ungureanu
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D018450:Disease Progression; D058851:GPI-Linked Proteins / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000090204:Mesothelin; D008654:Mesothelioma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000086002:Mesothelioma, Malignant; D058990:Molecular Targeted Therapy
D014408:Biomarkers, Tumor; D058851:GPI-Linked Proteins; D000090204:Mesothelin
antibodies; immunotoxin; mesothelin; mesothelioma; vaccines